These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16357140)

  • 1. Gene expression profiles associated with treatment response in oligodendrogliomas.
    French PJ; Swagemakers SM; Nagel JH; Kouwenhoven MC; Brouwer E; van der Spek P; Luider TM; Kros JM; van den Bent MJ; Sillevis Smitt PA
    Cancer Res; 2005 Dec; 65(24):11335-44. PubMed ID: 16357140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
    Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.
    Molinari C; Iorio P; Medri L; Ballardini M; Guiducci G; Cremonini AM; Cerasoli S; Riccioni L; Faedi M; Mariani GA; Zoli W; Silvestrini R; Calistri D
    Int J Mol Med; 2010 Jan; 25(1):145-51. PubMed ID: 19956913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
    J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p.
    Mukasa A; Ueki K; Matsumoto S; Tsutsumi S; Nishikawa R; Fujimaki T; Asai A; Kirino T; Aburatani H
    Oncogene; 2002 Jun; 21(25):3961-8. PubMed ID: 12037678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
    Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
    Sonabend AM; Lesniak MS
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
    Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
    Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.
    Zlatescu MC; TehraniYazdi A; Sasaki H; Megyesi JF; Betensky RA; Louis DN; Cairncross JG
    Cancer Res; 2001 Sep; 61(18):6713-5. PubMed ID: 11559541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q.
    Tews B; Roerig P; Hartmann C; Hahn M; Felsberg J; Blaschke B; Sabel M; Kunitz A; Toedt G; Neben K; Benner A; von Deimling A; Reifenberger G; Lichter P
    Oncogene; 2007 Jul; 26(34):5010-6. PubMed ID: 17311001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
    Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
    Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
    Ino Y; Betensky RA; Zlatescu MC; Sasaki H; Macdonald DR; Stemmer-Rachamimov AO; Ramsay DA; Cairncross JG; Louis DN
    Clin Cancer Res; 2001 Apr; 7(4):839-45. PubMed ID: 11309331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
    Gadji M; Fortin D; Tsanaclis AM; Drouin R
    Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral distribution of 1p loss in oligodendroglial tumors.
    Kros JM; van der Weiden M; Zheng PP; Hop WC; van den Bent MJ; Kouwenhoven MC
    J Neuropathol Exp Neurol; 2007 Dec; 66(12):1118-23. PubMed ID: 18090920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.